HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
SPOTLIGHTS
Pharma companies are partnering AI firms to advance drug discovery
Increasing investments in AI in drug discovery by big pharma companies allow them to apply machine learning to identify and screen potential drug candidates, says GlobalData.

Big pharma companies are partnering with artificial intelligence (AI) firms with hopes to improve key aspects of the healthcare industry such as drug discovery and ultimately save time and reduce R&D costs. However, it is important to train and monitor the performance of these systems to avoid errors such as security breaches, says data and analytics company GlobalData.

For several pharma companies, machine learning is the most important aspect of AI, with the potential to allow machines to ultimately surpass the intelligence levels of humans. Increasing investments in AI in drug discovery by big pharma companies allow them to apply machine learning to identify and screen potential drug candidates.

Merck is one of many pharma companies partnering with AI-focused companies to advance drug discovery. The pharmaceutical giant partnered with AI-based company Numerate, in 2012, to use its computer-based drug design technology to develop novel small molecule drug leads for an undisclosed cardiovascular disease target. Merck is also leveraging Atomwise’s AI-based technology to scan existing medicines that could be redesigned to fight old and upcoming diseases.

American biotech firm Celgene partnered with GNS Healthcare to use its Reverse Engineering and Forward Simulation causal machine learning and simulation platform. GSK entered into a $43m drug discovery collaboration with UK-based AI-driven startup Exscientia. Pfizer collaborated with IBM Watson for immuno-oncology drug discovery research.

Alexandra Annis, senior immunology analyst at GlobalData says, “The success of AI in drug discovery is largely due to deep learning, a field of machine learning that is built using artificial neural networks that model the way neurons in the human brain talk to each other. This technology can train systems to analyze large sets of chemical and biological data to identify drug candidates with high success rates much faster than humans.

“However, it is important that data scientists and developers monitor the performance of these systems and take the necessary steps to adjust or train the systems to avoid repeating any errors, such as security breaches. That being said, we anticipate AI to transform the drug discovery process as we know it.”

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy